Doximity Inc. (DOCS)
NYSE NYSE Primary 
XSTU 
Doximity (DOCS) Falls More Steeply Than Broader Market: What Investors Need to Know
Doximity (DOCS) closed at $60.55 in the latest trading session, marking a -1.51% move from the prior day.
Doximity (DOCS) Beats Stock Market Upswing: What Investors Need to Know
The latest trading day saw Doximity (DOCS) settling at $62.99, representing a +0.35% change from its previous close.
Buy These 5 Top-Ranked Stocks to Play Likely Earnings Beat
Top-ranked stocks Doximity (DOCS), Life Time Group Holdings (LTH), Adtalem Global Education (ATGE), BioMarin Pharmaceutical (BMRN) and Iridium Communications (IRDM) are likely to beat on the bottom line in their upcoming releases.
Buy 5 High-Flying Health & Fitness Stocks Year to Date With More Upside
Five Health & Fitness stocks have strong growth potential for 2025. These are: GRMN, SFM, DOCS, LTH, VFC.
Is Doximity (DOCS) a Solid Growth Stock? 3 Reasons to Think "Yes"
Doximity (DOCS) possesses solid growth attributes, which could help it handily outperform the market.
Doximity: Rating Downgrade As Near-Term Upside Is Priced In
I downgraded Doximity from buy to hold due to expected growth slowdown and current high valuation at 40.5x forward EBITDA. DOCS reported strong Q3 performance with $168.6 million revenue, 25% y/y growth, and 93.3% gross margin, driven by high pharma client demand. New ad products grew over 100% y/y, now contributing >20% of pharma revenue, showing strong underlying demand and expanding advertiser engagement.
Doximity Momentum, Big Money Support Stays Strong
Shares of Doximity, Inc. (DOCS) jump on business growth, investor inflows.
Doximity (DOCS) is an Incredible Growth Stock: 3 Reasons Why
Doximity (DOCS) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Why Doximity (DOCS) Might be Well Poised for a Surge
Doximity (DOCS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Doximity (DOCS) is a Great Momentum Stock: Should You Buy?
Does Doximity (DOCS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Doximity Q3 Earnings: Outpacing Even Management's Expectations
I previously rated Doximity, Inc. a buy due to strong Q2 earnings, favorable DCF analysis, and its strategic position in the healthcare industry. Q3 earnings showed continued strength, with DOCS stock up 56% compared to the S&P 500's 2% return since my last analysis. Updated DCF valuation, incorporating management guidance and industry trends, suggests a new price target of $90, indicating 14% upside from today.
Digital Health Platform Doximity Stock Jumps On Upbeat Annual Outlook, Analysts Raise Forecast
Doximity Inc DOCS stock is trading higher on Friday after the company reported third-quarter fiscal 2025 results that beat analysts' expectations and upbeat guidance.
